CNS Drug Discoveries: Multiple Sclerosis Chapter

Table of Contents

MULTIPLE SCLEROSIS

• EXECUTIVE SUMMARY
• THE FACTS
  • What is MS and why are we interested in it?
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
  • MS categories
    • Types of MS
• PATIENT MODEL
  • The treatable MS patient population will have a CAGR 2005-2012 = 4.6%
    • Summary of patient population forecasts
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

GLOBAL MS MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • Global sales split (2005A)
  • US market
    • MS US drugs sales split (2005A)
  • European market
    • MS European drugs sales split (2005A)
  • Japanese market
  • The major players
    • Market share of MS players by sales (Dec 2005A)
  • Players and Products in 2005 & 2006
  • Players and products in 2012
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of Leading MS Agents
  • Current Products Patent Exposure
    • Patent Exposure of Leading Brands
• ANALYSIS OF LEADING BRANDS
  • Disease-modifying agents
• Disease-modifying agents
  • Avonex (Biogen Idec/Genzyme)
  • Betaferon/Betaseron (Berlex/Schering AG)
  • Copaxone (Teva)
  • Rebif (Serono)
  • Tysabri
  • Novantrone (Serono)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005-2012
  • Sales Forecasts of Current Leading MS Drugs
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat MS
• ANALYSIS OF PHASE III DRUGS
  • New Drugs in Phase III Development to Treat MS
  • Disease-modifying agents
  • MS Symptoms
  • Campath (Genzyme/Schering AG)
  • FTY720 (Novartis)
  • Laquinimod (Teva/Active Biotech)
  • MBP8298 (BioMS)
  • Mylinax (Serono/Ivax)
  • Rituxan (Genentech/Biogen Idec/Roche/Chugai/Zenyaju Kogyo)
  • Teriflunomide (sanofi-aventis)
• MS Symptoms
  • Neurelan (Elan/Acorda)
    • Trial MS-F202: Timed 25-foot walk response rate of MS patients treated with Fampridine SR
• GLOBAL SALES FORECASTS OF PHASE III MS DRUGS 2006-2012
  • Sales Forecasts of Phase III Developmental MS Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat MS
  • Disease-modifying agents
  • Vaccines
• Disease-modifying agents
  • ABT-874 (Abbott)
  • ATL1102 (Antisense/ISIS pharmaceuticals)
  • BG-12 (Biogen Idec)
  • Daclizumab (Biogen Idec/BioPharma)
  • SB-683699 (GlaxoSmithKline/Tanabe Seiyaku)
• Vaccines
  • NeuroVax (TIRC)
  • Tovaxin (Opexa Therapeutics)
  • Other Interesting Phase II Drugs
• GLOBAL SALES FORECASTS OF PHASE II MS DRUGS 2006 - 2012
  • Sales Forecasts of Phase II Developmental MS Drugs
  • Model assumptions
• COMPETITOR RATIO ANALYSIS - PRODUCTS
  • CR Analysis of MS Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of MS Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the MS Market by 2012
  • Winners
  • Losers
• DISCONTINUATION OF DRUGS
  • MS Drugs Discontinued from Clinical Development
• MS APPENDIX 1
  • Clinical diagnostic test for MS
• MS APPENDIX 2
  • Expanded Disability Status Scale (EDSS)
• MS APPENDIX 3
  • Phase transition probability
    • Probability of launch
• MS APPENDIX 4
  • Patient Model
    • Summary of US MS Patient Population Forecasts
    • Summary of Europe (Tope 5) MS Patient Population Forecasts
    • Summary of Japan MS Patient Population Forecasts
• MS APPENDIX 5
  • Global MS Drugs Sales 2005-20012
    • Global MS Drug Sales 2005A-2012E
• Ms APPENDIX 6
  • Competitor Ratio Analysis Criteria
    • Key MS Drugs on the Market by 2012
• MS GLOSSARY
• MS REFERENCES
• ACRONYMNS